Eli Lilly and Company (NYSE:LLY) Shares Up 3.8% – Here’s What Happened

Eli Lilly and Company (NYSE:LLY) was up 3.8% during mid-day trading on Wednesday. The stock traded as high as $1,216.71 and last traded at $1,211.0830. 3,129,240 shares traded hands during trading, an increase of 6% from the average daily volume of 2,953,200 shares. The stock had previously closed at $1,166.51.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts at Erste Group raised their FY2026 EPS estimate for Eli Lilly to $36.55 from $36.45 and their FY2027 estimate to $47.30 from $47.18, reinforcing expectations for continued earnings growth. Analyst earnings estimates
• Positive Sentiment: Lilly-backed TRex Bio raised $116.7 million in an initial public offering. Although the transaction is not a direct Lilly financing event, the IPO provides validation and potential funding for a partner developing treatments in immunology and autoimmune disease. TRex Bio IPO
• Positive Sentiment: Prelude Therapeutics and Lilly announced a clinical collaboration to test Prelude’s experimental KAT6A degrader in combination with established breast-cancer therapies. Enrollment is expected to begin in the fourth quarter of 2026, adding another potential catalyst to Lilly’s oncology pipeline. Prelude and Lilly collaboration
• Positive Sentiment: Investor commentary continues to highlight Lilly’s strong obesity-drug franchise, broad pipeline and potential for retatrutide to become a major future growth driver beyond Zepbound. Retatrutide outlook
• Neutral Sentiment: Investors are awaiting the October 29 earnings report, with analysts expecting continued earnings growth. Results, guidance and updates on retatrutide will likely determine whether Lilly’s premium valuation can be sustained. Lilly earnings preview
• Negative Sentiment: A reported combination study produced greater weight loss than Zepbound but also had substantially higher discontinuation rates, highlighting tolerability and adherence risks for Lilly’s next-generation obesity medicines. Weight-loss combination study

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on LLY. UBS Group set a $1,376.00 price target on Eli Lilly and Company in a research note on Friday, August 7th. The Goldman Sachs Group raised their target price on Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the company a “buy” rating in a report on Thursday, September 17th. Cantor Fitzgerald boosted their target price on shares of Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an “overweight” rating in a research report on Thursday, October 8th. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an “overweight” rating in a research note on Monday, September 28th. Finally, Guggenheim increased their price target on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a report on Friday, September 18th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,313.43.

Eli Lilly and Company Stock Up 3.8%

The stock has a market capitalization of $1.14 trillion, a PE ratio of 40.64, a P/E/G ratio of 1.52 and a beta of 0.46. The firm has a 50 day moving average of $1,176.60 and a two-hundred day moving average of $1,102.08. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. Eli Lilly and Company’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period in the previous year, the business earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 34.79 earnings per share for the current year.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 in the last three months. Corporate insiders own 0.14% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently bought and sold shares of the stock. Osbon Capital Management LLC purchased a new stake in Eli Lilly and Company in the 4th quarter worth approximately $25,000. Basso Capital Management L.P. acquired a new position in Eli Lilly and Company in the fourth quarter valued at $30,000. Maseco LLP lifted its position in Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after buying an additional 28 shares during the period. Aventus Investment Advisors Inc. boosted its stake in Eli Lilly and Company by 270.0% in the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after buying an additional 27 shares during the last quarter. Finally, Marshall & Sterling Wealth Advisors Inc. grew its holdings in Eli Lilly and Company by 60.0% in the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after buying an additional 15 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.